It is made available under a CC-BY-NC-ND 4.0 International license .

### 1 Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination

2 in South Korea

3 Running title: Real-World Effectiveness of COVID-19 Vaccination

- 4 **Authors**: Eunseon Gwak<sup>a,\*</sup>, Seung-Ah Choe<sup>a,b,\*</sup>, Kyuwon Kim<sup>a</sup>, Erdenetuya Bolormaa<sup>a</sup>,
- 5 Jonathan Fix<sup>c</sup>, Muruga Vadivale<sup>c</sup>, Matthew D. Rousculp<sup>c,\*</sup> and Young June Choe<sup>d,e,\*</sup>
- 6 Affiliations: <sup>a</sup> Korea University College of Medicine, Department of Preventative Medicine,
- 7 Seoul, Korea; <sup>b</sup>Research and management center for health risk of particulate matter, Korea
- 8 University, Seoul, Korea; <sup>c</sup>Novavax, Inc., Gaithersburg, MD, USA; <sup>d</sup>Korea University Anam
- 9 Hospital, Department of Pediatrics, Seoul, Korea; <sup>e</sup>Korea University, Allergy and Immunology
- 10 Center, Seoul, Korea
- 11 \*Equally contributed to the manuscript
- 12 Co-Correspondence: Young June Choe, MD, PhD. Department of Pediatrics, Korea University
- 13 College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Korea, choey@korea.ac.kr
- 14 and Matthew D. Rousculp, PhD, MPH, Novavax, Inc., Gaithersburg, MD 20878, USA,
- 15 mrousculp@novavax
- 16
- 17 **Abstract:** 196/200
- 18 **Text:** 2949 (no limit noted online)
- 19 **Tables/Figures:** 2/3 (no limit noted online)
- 20 **References:** 33
- 21
- 22
- 23
- 24
- 25

It is made available under a CC-BY-NC-ND 4.0 International license .

### 26 **Abstract** (196/200)

Objectives: In February 2022, NVX-CoV2373 became available in South Korea; real-world
 effectiveness of multiple doses compared with mRNA-based vaccines has not been thoroughly
 evaluated.

30 *Methods*: This retrospective study identified NVX-CoV2373 and BNT162b2 recipients aged  $\geq 12$ 

31 years from the K-COV-N database. Vaccine groups were propensity score–matched based on

demographic characteristics, Seoul capital area residence, income level, comorbidity/disability,

prior SARS-CoV-2 infection, and prior vaccination dose/timing. Outcomes were any and severe

34 (intensive-care-unit admission or death within 8 weeks of infection) laboratory-confirmed

35 SARS-CoV-2 infection assessed from 7 days after the third and fourth dose. Adjusted hazard

ratios (aHRs) from matched groups measured vaccine effectiveness up to a 180-day risk window.

37 *Results*: From February–December 2022, 923,833 NVX-CoV2373 and 1,286,604 BNT162b2

doses were administered. The 180-day risk-window aHRs (95% CI) for NVX-CoV2373

compared with BNT162b2 for any SARS-CoV-2 infection were 0.78 (0.76–0.79) post third dose

and 0.86 (0.86–0.87) post fourth dose. The 180-day aHRs (95% CI) for severe infection were

41 0.73 (0.53-1.00) after the third dose and 1.21 (1.03-1.42) after the fourth dose.

42 *Conclusions*: NVX-CoV2373 demonstrated favorable and similar effectiveness against any and

43 severe SARS-CoV-2 infection, respectively, compared with BNT162b2, with evidence of

44 enhanced NVX-CoV2373 durability.

45

46

47 **Keywords:** COVID-19 vaccines; mRNA vaccines; heterologous; NVX-CoV2373; SARS-CoV-2

48 infection; vaccine effectiveness; seasonal vaccination; adjuvant; protein-based vaccine

It is made available under a CC-BY-NC-ND 4.0 International license .

### 50 Introduction

The continual emergence of new SARS-CoV-2 variants has resulted in a persistent global burden 51 52 of infection and cases of COVID-19.(1) Several types of vaccines against SARS-CoV-2 have been developed, many of which are now authorized or approved by local regulatory agencies in 53 Korea(2) and across the globe.(3) In 2022, authorized or approved SARS-CoV-2 vaccines 54 included messenger ribonucleic acid (mRNA)-based BNT162b2 (Comirnaty<sup>®</sup>, Pfizer-BioNTech; 55 approved) and mRNA-1273 (Spikevax<sup>™</sup>, Moderna, Inc.; authorized), adenoviral vector-based 56 57 Ad26.COV2.S (Johnson & Johnson/Janssen; no longer available in the United States [US] as of 58 June 2023), and protein nanoparticle NVX-CoV2373 (Nuvaxovid<sup>TM</sup>, Novavax, Inc.; authorized).(3) The primary series of authorized mRNA and protein-based COVID-19 vaccines 59 60 consist of two doses administered 28 or 21 days apart.(4-7) The Korean Disease Control and Prevention Agency (KDCA) and World Health Organization (WHO) recommend additional 61 62 doses of COVID-19 vaccines for high-risk populations, including individuals aged >65 years 63 (KDCA) or >50 years (WHO) and individuals who are immunocompromised.(8, 9) The immuneevading capabilities of emerging variants(10) has required updates to vaccine strain 64 compositions,(11) including a bivalent (ancestral and variant, combined) vaccine in 2022 and a 65 change to monovalent Omicron XBB.1.5-based vaccines for 2023-2024(12). The most recent 66 67 guidance is to target the JN.1 lineage of SARS-CoV-2 for 2024–2025.(13) Pivotal studies with NVX-CoV2373 demonstrated high efficacy against SARS-CoV-2 68 69 infection in the US, Mexico, and the United Kingdom.(14, 15) As NVX-CoV2373 has been 70 globally integrated into national immunization programs, including in South Korea, it is 71 imperative to assess its real-world effectiveness. Although randomized-controlled trials investigating NVX-CoV2373 or mRNA-based vaccines have separately reported vaccine 72 73 efficacy, (14, 16, 17) cross-trial comparisons present confounding factors (eg, study design, patient population, timing of studies), preventing additional conclusions from being made. 74 75 Furthermore, real-world data on the relative effectiveness of multiple doses of NVX-CoV2373 in the general population are limited to the primary series and/or smaller populations. (18-22) 76 In South Korea, studying vaccine effectiveness with data from 2022 provides a unique 77 research opportunity. Beginning in February 2020, the South Korean government instituted 78 79 active epidemiological investigations, strict isolation of affected individuals, and extensive

It is made available under a CC-BY-NC-ND 4.0 International license .

80	public lockdowns, which led to the country experiencing minimal impact from the COVID-19
81	pandemic.(23) With the loosening of these restrictions in late 2021, South Korea quickly
82	experienced the highest incidence rate (IR) of infection in the world. From mid-February to mid-
83	April 2022, the SARS-CoV-2 infection cases exceeded 600,000/day, yet the country maintained
84	one of the lower mortality rates globally. This relatively high infection rate persisted throughout
85	most of 2022 and included varied waves of Omicron variants (BA.1/1.1, BA.2/2.3, BA.5/5.2).(24)
86	The primary goal of this retrospective cohort study was to estimate the relative
87	effectiveness of third and fourth vaccine doses of NVX-CoV2373 compared with BNT162b2 in
88	preventing any and severe laboratory-confirmed SARS-CoV-2 infection during the early
89	Omicron variant dominance in South Korea(25) using population-based data.
90	Methods
91	Study design and population
92	This retrospective, observational study used the K-COV-N cohort,(26) which links the
93	KDCA and National Health Insurance Service (NHIS) databases to provide COVID-19
94	vaccination and health outcome data. Anonymized data for vaccination date, dose, type, location,
95	and lot number were linked to participant demographics and healthcare resource utilization (in
96	respect to SARS-CoV-2 infection). The collected data were analyzed at the NHIS data analysis
97	center.
98	This analysis included residents of Korea from February 1, 2022, through December 31,
99	2022, aged $\geq$ 12 years who received at least one dose of NVX-CoV2373 or BNT162b2. A
100	minimum of 365 days of observation prior to the date of vaccination and complete medical
101	outcome data were required. Heterologous or homologous booster (third or fourth) doses were
102	permitted; however, primary series effectiveness was only assessed in individuals with
103	homologous first and second doses.
104	The primary objective was evaluation of relative effectiveness of third and fourth doses
105	of NVX-CoV2373 compared with matched individuals who received BNT162b2. The secondary
106	objective was evaluation of effectiveness of a homologous primary series of NVX-CoV2373
107	compared with that of a matched group who received a homologous primary series of BNT162b2.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 108 *Outcomes and Assessments*

109 Outcomes of interest were any and severe laboratory-confirmed SARS-CoV-2 infection 110 after vaccination. The primary outcome measure was laboratory-confirmed SARS-CoV-2 infection, determined through rapid antigen tests (RATs) or polymerase chain reaction (PCR) 111 112 administered by healthcare professionals. Results from self-administered RATs were not reported to the government.(19) Hospitalization was not included as an outcome measure in the 113 114 assessment of vaccine effectiveness due to South Korea public health policy during the study period, which mandated hospitalization of individuals testing positive for SARS-CoV-2 (for 115 116 quarantine purposes) regardless of symptom severity.(27) Severe SARS-CoV-2 infection was defined as admission to an intensive care unit (ICU) or death due to and within 30 days of 117 infection. ICU admissions attributed to SARS-CoV-2 infection/COVID-19 were identified using 118 specific treatment codes for ICU admission, coupled with a primary or secondary diagnosis of 119 SARS-CoV-2-related conditions (ICD-10 codes: B342, B972, Z208, Z290, Z115, U181, Z038, 120 U071, U072, U08, U09, and U10). Given the unavailability of precise cause-of-death data, any 121 death occurring within 8 weeks of a confirmed SARS-CoV-2 infection was assumed to be related 122 123 to COVID-19. This 8-week window was established based on the upper range observed in previous studies for the time between symptom onset and COVID-19–related death.(28) 124

#### 125 Analyses

The date of vaccine dosing (third dose, fourth dose, or first dose of primary series) was considered the index date (Day 0). First, availability of third and fourth doses were March 7, 2022, and March 14, 2022, respectively, and any post-primary series doses received prior to these dates were considered invalid and subsequently excluded. Participant follow-up for vaccine effectiveness began 7 days after receipt of the third and fourth doses and 14 days after the second dose of the primary series.

### 132 *Statistical analysis*

Individuals who received NVX-CoV2373 were matched to recipients of BNT162b2 through propensity scores, which were estimated based on demographic characteristics, relative level of income, residential region (Seoul capital area or not), disability registration, prior SARS-CoV-2 infection history, Charlson comorbidity index assessed based on the all diagnosis records from 2021 and month of COVID-19 vaccination. Income was categorized as medical aid

It is made available under a CC-BY-NC-ND 4.0 International license .

beneficiary (no/lowest income) and then into quartiles of 10%-40%, >40%-60%, >60%-80%,

and >80%–100%. Participants who received NVX-CoV2373 were matched to BNT162b2

140 recipients, with adjustments for confounding by balancing the baseline characteristics between

141 the two groups using the absolute standardized difference (aSD), where a value >0.1 indicated a

significant imbalance.

To assess relative vaccine effectiveness, IRs per 1000 person-days and adjusted hazard 143 ratios (aHRs), for any and severe laboratory-confirmed infections, were calculated for the 144 matched sets. Time-varying exposure to the vaccines was considered, following individuals from 145 7 days (14 days for primary series) post vaccination until COVID-19 diagnosis, death, end of 146 follow-up (cumulative 30-days per risk window), receipt of an additional COVID-19 dose, or 147 study end. Vaccine effectiveness was assessed every 30 days for up to 180 days of follow-up and 148 in the following risk windows: 30, 60, 90, 120, 150, and 180 days. To quantify potential residual 149 confounding in the vaccine effectiveness estimates, a negative control exposure (recent 150 151 vaccination) was evaluated by calculating adjusted odds ratios (aORs) for any SARS-CoV-2 infection, (29) comparing NVX-CoV2373 recipients to matched BNT162b2 recipients during 152 days 0–5 post vaccination; as there should not be an effect of either vaccine during this period, 153 154 any observed association would indicate residual confounding at baseline. Statistical analyses were conducted using SAS<sup>®</sup> 9.4. 155

#### 156 *Ethical oversight*

This study was conducted in compliance with ethical standards and relevant local regulations. Formal review by an institutional review board was not required for this type of research (Korea University Institutional Review Board exemption No. 2023AN0124).

160 **Results** 

### 161 *Population and doses administered*

A total of 923,833 NVX-CoV2373 and 1,286,604 BNT162b2 doses administered to the national population of South Korea between February 1, 2022, and December 31, 2022, were included in this study. Among those vaccinated, 209,982 individuals were excluded from this analysis for not having received a homologous primary series (Fig. 1). After receipt of a homologous primary series, a heterologous or homologous third dose of NVX-CoV2373 was received by 127,275 individuals and BNT162b2 by 254,841 individuals; 505,607 and 978,874

It is made available under a CC-BY-NC-ND 4.0 International license .

individuals received a fourth dose of NVX-CoV2373 and BNT162b2, respectively. Propensity
score matching (as described in the Methods) resulted in the following NVX-CoV2373 to
BNT162b2 ratios for outcomes assessment: third dose, ~1:2; fourth dose, 1:1; primary series,
~3:1.

There was a significantly greater proportion of matched third dose recipients of NVX-CoV2373 versus BNT162b2 who were aged 40–49 years, male, were employed, or were in the highest income quartile (Table 1). A significantly higher proportion of individuals who received a third dose of BNT162b2 than NVX-CoV2373 were aged 70–79 years or >80 years or were female. No significant differences were observed between the vaccine groups for the fourth-dose

177 recipients (Table 1) or for the primary-series recipients (Supplement 1).

178 Incidence of SARS-CoV-2 infection after third or fourth COVID-19 vaccination

Within the 30-day risk window, SARS-CoV-2 infection occurred in 6455 (IR/1000
person-days=2.76, 95% CI: 2.70–2.83) participants who received a third dose of NVX-CoV2373

and in 9799 (2.86 [2.80–2.91]) participants who received a third dose of BNT162b2 (Table 2).

182 There were 10 (IR=0.00 [95% CI: 0.00–0.01]) and 32 (0.01 [0.01–0.01]) individuals with severe

183 SARS-CoV-2 infection in the 30-day risk window after the third dose of NVX-CoV2373 and

184 BNT162b2, respectively. Of individuals who received a fourth COVID-19 vaccination, there

185 were 11,306 (IR=0.78 [95% CI: 0.77–0.79]) NVX-CoV2373 recipients and 9115 (0.63 [0.61–

186 0.64]) BNT162b2 recipients with any SARS-CoV-2 infection within the 30-day risk window;

severe infection was observed in 30 (0.00 [0.00–0.00]) and 21 (0.00 [0.00–0.00]) recipients,

188 respectively.

189 In the 180-day risk window after the third dose, any SARS-CoV-2 infection was

190 detected in 23,820 (IR=1.91 [95% CI: 1.89–1.94]) recipients of NVX-CoV2373 and 40,214

191 (2.27 [2.25–2.29]) recipients of BNT162b2 (Table 2). The cumulative incidence of severe

192 SARS-CoV-2 infection was 53 and 148 cases, respectively, for recipients of NVX-CoV2373

193 (IR=0.00 [95% CI: 0.00–0.00]) and BNT162b2 (0.01 [0.01–0.01]). Within the 180-day risk

194 window for individuals who received a fourth dose of NVX-CoV2373, there were 106,377

195 (IR=1.37 [95% CI: 1.36–1.37]) individuals who experienced SARS-CoV-2 infection; 116,057

196 (1.50 [95% CI 1.49–1.51]) recipients of BNT162b2 had a reported infection. Cumulative cases

of severe infection after the fourth dose were observed in 330 (IR=0.00 [95% CI: 0.00–0.00])

It is made available under a CC-BY-NC-ND 4.0 International license .

- and 289 (0.01 [0.01–0.01]) recipients of NVX-CoV2373 and BNT162b2, respectively. Outcomes
- among each of the risk windows demonstrated a similar trend with one another (Table 2).
- 200 Cumulative risk of any SARS-CoV-2 infection since the third and fourth dose of either vaccine
- is shown in Fig. 2.

### 202 SARS-CoV-2 infection risk comparison among vaccination groups

- 203 The aHR (95% CI) for NVX-CoV2373 compared with BNT162b2 for any SARS-CoV-2
- infection in the 30-day risk window after the third dose was 0.94 (95% CI: 0.91–0.97) and for
- severe infection was 0.66 (0.32–1.35; Table 2; Fig. 3). Risk estimates (aHR [95% CI]) observed
- for the 180-day risk window after the third dose were 0.78 (95% CI: 0.76–0.79) for any SARS-
- 207 CoV-2 infection and 0.73 (0.53–1.00) for severe infection. Among individuals who received a
- 208 fourth dose, the aHR of SARS-CoV-2 infection in the 30-day risk window was higher for
- recipients of NVX-CoV2373 compared with BNT162b2 (any infection=1.19 [95% CI: 1.16–
- 1.23]; severe infection=1.37 [0.78–2.42]). For the 180-day risk window after the fourth dose,
- 211 NVX-CoV2373 compared with BNT162b2 was associated with a lower risk estimate for overall
- 212 infection (aHR=0.86 [95% CI: 0.86–0.87]); for severe infection, there was an aHR of 1.21 (95%
- CI: 1.03–1.42). Incidence and hazard ratios of any and severe SARS-CoV-2 infections for
- homologous, primary series recipients of NVX-CoV2373 or BNT162b2 are available in
- Supplements 2 and 3. Cumulative rates are shown in Supplement 4.

#### 216 Evaluation of residual bias/confounding using the recently vaccinated period

- The odds of any infection during days 0–5 post vaccination were generally similar
- between the NVX-CoV2373 and BNT162b2 cohorts for both the third dose and primary series
- 219 (Supplement 5). For the fourth dose, the odds of any infection were significantly higher among
- 220 the NVX-CoV2373 versus BNT162b2 group (aOR=1.16 [95% CI: 1.07–1.25]).

# 221 **Discussion**

- 222 This analysis represents the largest real-world, population-based assessment of NVX-
- 223 CoV2373 effectiveness to date. IRs of any laboratory-confirmed SARS-CoV-2 infection between
- the NVX-CoV2373 and BNT162b2 groups across the defined risk windows, after heterologous
- or homologous third and fourth doses, favored the effectiveness of the NVX-CoV2373 vaccine.
- 226 No clinically meaningful difference was observed across the IRs for severe SARS-CoV-2

It is made available under a CC-BY-NC-ND 4.0 International license .

infection. Over the 180-day follow-up, the relative effectiveness of NVX-CoV2373, compared
with BNT162b2, appeared to improve with time. The clinical meaning and public health
implications of these findings require further investigation.

The observed improvements in vaccine effectiveness over time for NVX-CoV2373 230 231 compared with BNT162b2 may reflect the rapid waning of protective effects of the mRNAbased vaccines, which has been previously reported.(30) In the systematic review and meta-232 233 analysis by Menegale et al., vaccine effectiveness against symptomatic disease from 1 to 9 months post primary series decreased from 80% to 50% against Delta variant infection and from 234 235 53% to 9% against Omicron infection. Diminished vaccine effectiveness over time is a concern and long-term real-world monitoring will be valuable in determining durability of responses to 236 237 initial (primary series) and subsequent vaccinations, as well as among the different formulations and vaccine updates. Evidence for enhanced durability of NVX-CoV2373 compared with mRNA 238 vaccines has also been implied by the observed persistence of humoral responses over time. In an 239 8-month follow-up analysis of the COV-BOOST trial, a heterologous third dose of NVX-240 CoV2373 following a BNT162b2 primary series had a significantly slower decay rate of anti-241 spike immunoglobulin G levels compared with three homologous BNT162b2 doses.(31) While it 242 243 is likely that serum antibody responses play a role in SARS-CoV-2 vaccine durability, there are other vaccine type-specific effector and memory responses that influence durability and cross-244 245 reactivity, which remain poorly understood and require additional research.

246 This study provides a unique perspective on outcomes assessment by vaccine history via the inclusion of heterologous doses after the primary series. While effectiveness outcomes 247 248 reported in this study focused on booster doses, comparable levels of protection have been previously reported in observational investigations of vaccine-naive populations. A retrospective 249 250 analysis accessing data in the K-COV-N database was conducted among adults without prior SARS-CoV-2 infection who received their first three doses of a COVID-19 vaccine from 251 252 February–November 2022.(32) The 40-week assessment reported a low risk of any or severe 253 SARS-CoV-2 infection with either NVX-CoV2373 or BNT162b2 (N≈3000 for each group). 254 Another study reported low rates of COVID-19 among matched cohorts of Korean adults who received a homologous primary series of NVX-CoV2373 (N=47,078) or BNT162b2 255 256 (N=7561).(33) Data from February–April 2022 indicated similar rates of COVID-19 at 30, 60, and 90 days post primary series and a 22-week risk ratio for NVX-CoV2373 to BNT162b2 of 1.1. 257

It is made available under a CC-BY-NC-ND 4.0 International license .

In a separate assessment of COVID-19 vaccine–naive adolescents (aged 12–17 years) in South

Korea who received both doses of a homologous primary series (NVX-CoV2373 or BNT162b2)

from September–December 2022, there was noninferiority among the two matched cohorts (each

N=465) for SARS-CoV-2 infection.(19) Notably, the observation periods for each of these

studies(19, 32, 33) were when early Omicron variants (eg, BA.1 BA.2, BA.2.3, and BA.4/5)

were predominant,(25) suggesting benefits of the prototype vaccine against variant strains with

spike mutations.

Propensity score matching was used to control for baseline differences between the 265 vaccinated populations; however, residual and unmeasured confounding remained a potential 266 concern. Residual confounding was evaluated through a negative control analysis, comparing the 267 odds of SARS-CoV-2 infection during days 0–5 post vaccination between each group, at which 268 point the vaccine would not yet be effective. While this approach does not address time-varying 269 confounding or other biases (eg, selection bias), it helps demonstrate how well the control 270 271 variables in the statistical model account for baseline differences between the vaccinated populations. The odds of infection were higher for NVX-CoV2373 than BNT162b2 recipients 272 273 following the fourth dose, suggesting that fourth-dose NVX-CoV2373 recipients might have had 274 a higher baseline risk for medically attended SARS-CoV-2 infection and/or could have been 275 more likely to seek healthcare compared with their matched counterparts.

276 One limitation of this study is the timing of the study period, which coincided with the 277 largest COVID-19 outbreak in South Korea (mid-February to mid-April 2022), driven by the Omicron variant, and resulting in an increase in cases to the highest incidence (>600,000 278 279 cases/day) observed at that time.(23) This extraordinary surge in infections placed immense 280 strain on the healthcare system, potentially impacting the accuracy of data collection and 281 reporting. Moreover, the widespread transmission during this period might have influenced individuals' behaviors and adherence to preventive measures, further complicating the 282 283 assessment of vaccine effectiveness; however, robust community testing and uniform testing 284 recommendations in South Korea should have helped mitigate differences in health-seeking 285 behavior among the populations included. Another limitation is that only prototype vaccine formulations targeting ancestral SARS-CoV-2 were evaluated. There was likely a period during 286 287 the study where SARS-CoV-2 variants were in circulation; however, strain genotypes for individual cases of breakthrough infections are unknown. As such, a mismatch between the 288

It is made available under a CC-BY-NC-ND 4.0 International license .

289	vaccine target protein and the infecting strain may cause a decrease in vaccine effectiveness
290	estimates in the latter part of the study, particularly when there is minimal or no cross protection;
291	however, some degree of vaccine target to circulating strain mismatch is consistent across
292	COVID-19 vaccine studies, based on the rapid mutation and selection pressure of SARS-CoV-2.
293	Finally, a low number of severe disease cases limited the precision of this specific outcome
294	analysis.
295	Overall, this large real-world assessment of NVX-CoV2373 supplies evidence for its
296	effectiveness in the general population. Data indicate the favorable vaccine effectiveness of
297	NVX-CoV2373 compared with the mRNA-based vaccine, BNT162b2, in preventing any SARS-
298	CoV-2 infection and the potential of an enhanced durable protection from SARS-CoV-2
299	infection.
300	
301	<b>Funding:</b> Funding was provided by Novavax, Inc.
302	
303	Author contributions
304	E.G., SA.C., M.V., M.D.R., and Y.J.C. conceptualized the trial and contributed to its design.
305	E.G., SA.C., K.K., and E.B. were involved in the extraction and analysis of data. E.G., SA.C.,
306	K.K., E.B., J.F., M.V., M.D.R., and Y.J.C. were involved in the interpretation of data. E.G., S

307 A.C., K.K., E.B., and Y.J.C. verified the data. E.G., S.-A.C., K.K., E.B., J.F., M.V., M.D.R., and

308 Y.J.C. drafted the manuscript. E.G., S.-A.C., and K.K. performed the statistical analyses. S.-A.C.,

J.F., M.D.R., and Y.J.C. supervised the study. All authors critically reviewed and approved themanuscript.

- 311
- 312

# 313 Data availability

The data used in this study are from the K-CoV-N cohort, which is not publicly available.

Researchers can apply for access to these data through the National Health Insurance Service

316 (NHIS) and Korea Disease Control and Prevention (KDCA) data linkage system. Applications

317 can be submitted via the Health Care Data Linkage (HCDL) website (<u>https://hcdl.mohw.go.kr/</u>)

318 and are subject to review by the relevant authorities.

It is made available under a CC-BY-NC-ND 4.0 International license .

3	1	9
-	_	-
-	-	-

# 320 **Declaration of Competing Interest**

EG, S-AC, KK, EB, and YJC are study investigators and do not have any conflicts of interest to

322 report.

- JF and MDR are salaried employees of Novavax, Inc. and may own stock.
- 324 MV was a salaried employee of Novavax, Inc, and may own stock.
- 325

# 326 Acknowledgments

- 327 This study used the Korea Disease Control and Prevention Agency (KDCA) and National Health
- Insurance Service (NHIS) databases for policy and academic research (KDCA-NHIS-2023-1-
- 494). The conclusions of this study are not related to this institution. Medical writing and
- editorial support were provided by Kelly M. Fahrbach, PhD, CMPP, and Ebenezer M. Awuah-
- 331 Yeboah, BS, of Ashfield MedComms (New York, USA), an Inizio company, supported by
- Novavax, Inc. The authors also thank doctors Mark Thompson and Chengbin Wang for their
- input on study initiation.
- 334

# 335 Appendix A. Supporting information

336 Supplementary data associated with this article can be found in the online version.

337

338

It is made available under a CC-BY-NC-ND 4.0 International license .

### 340 **References**

Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Consortium C-GU, et al. 341 1. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 342 343 2023;21(3):162–77. Ministry of Food and Drug Safety. COVID-19 Vaccine Regulatory Website; 2024. 344 2. Available from: <a href="https://www.mfds.go.kr/vaccine">https://www.mfds.go.kr/vaccine</a> covid19.jsp>. 345 World Health Organization. COVID-19 Vaccine Tracker; 2022. Available from: 346 3. <https://covid19.trackvaccines.org/agency/who/>. 347 European Medicines Agency. Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted); 4. 348 2024. Available from: <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid">https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid</a>>. 349 European Medicines Agency. Comirtaty COVID-19 mRNA vaccine; 2024. Available 350 5. from: <<u>https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty>.</u> 351 European Medicines Agency. Spikevax COVID-19 mRNA vaccine; 2024. Available 352 6. from: <https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-353 354 vaccine-moderna>. 355 7. Korea Disease Control and Prevention Agency. Infectious Diseases Portal; 2024. Available from: <a href="https://dportal.kdca.go.kr/pot/index.do#none">https://dportal.kdca.go.kr/pot/index.do#none</a>>. 356 World Health Organization. COVID-19 advice for the public: Getting vaccinated; 2023. 357 8. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-358 359 vaccines/advice>. Korean Disease Control and Prevention Agency. COVID-19 Vaccination 2024; 2024. 360 9. Available from: 361 <a href="https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kr/pot/www/CVID19/PRVNTN/VCNTN.jsp?seq=TAB2\_9>">https://dportal.kdca.go.kdca. 362 Ao D, He X, Hong W, Wei X. The rapid rise of SARS-CoV-2 Omicron subvariants with 363 10. immune evasion properties: XBB.1.5 and BQ.1.1 subvariants. MedComm (2020) 2023;4(2):e239. 364 Korean Disease Control and Prevention Agency. Immunization Guidelines 2024; 2024. 365 11. 366 Available from: <<u>https://nip.kdca.go.kr/irhp/infm/goVcntInfo.do?menuLv=1&menuCd=162</u>>. World Health Organization. Statement on the antigen composition of COVID-19 367 12. 368 vaccines; 2023. Available from: <a href="https://www.who.int/news/item/18-05-2023-statement-on-the-">https://www.who.int/news/item/18-05-2023-statement-on-the-</a> antigen-composition-of-covid-19-vaccines>. 369 370 13. European Medicines Agency. EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025; 2024. Available from: < 371 372 https://www.ema.europa.eu/en/documents/other/ema-recommendation-update-antigeniccomposition-authorised-covid-19-vaccines-2024-2025 en.pdf-0>. 373 Dunkle LM, Kotloff KL, Gay CL, Anez G, Adelglass JM, Barrat Hernandez AQ, et al. 374 14. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. NEJM 375 376 2022;386(6):531-43. 377 15. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the 378 379 Placebo-Controlled Phase of a Randomized Controlled Trial. Clin Infect Dis 2023;76(3):398-380 407. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety 381 16. of the mRNA-1273 SARS-CoV-2 vaccine. NEJM 2021;384(5):403-16. 382 17. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and 383 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. NEJM 2020;383(27):2603-15. 384

- 18. Gwak E, Choe S-A, Bolormaa E, Choe YJ, Wang C, Fix J, et al. Short-Term Relative
- Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-19 Vaccinations in South Korea. *medRxiv* [preprint] 2024. DOI: 10.1101/2024.07.02.24309830.
- 19. Lee ES, Choe YJ, Choe SA, Gwak ES, Kwon D. Relative Effectiveness of the NVX-
- CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents. *Pediatr Infect Dis J* 2024.
- 20. Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, et al. Early Estimates
- of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against
- 393 Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among
- 394Immunocompetent Adults Increasing Community Access to Testing Program, United States,
- 395 September 2023-January 2024. *MMWR Morb Mortal Wkly Rep* 2024;**73**(4):77-83.
- 21. Liu B, Stepien S, Qian J, Gidding H, Nicolopoulos K, Amin J, et al. Comparative
- 397 effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19
- and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection. *Vaccine*
- 399 2023;**41**(38):5587–91.
- 400 22. Mateo-Urdiales A, Sacco C, Petrone D, Bella A, Riccardo F, Del Manso M, et al.
- 401 Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373
  402 Against COVID-19. *JAMA Netw Open* 2023;6(10):e2336854.
- 403 23. Lim S, Sohn M. How to cope with emerging viral diseases: lessons from South Korea's
- strategy for COVID-19, and collateral damage to cardiometabolic health. *Lancet Reg Health West Pac* 2023;30:100581.
- 406 24. Kim IH, No JS, Kim JA, Park AK, Lee H, Kim JM, et al. Genomic epidemiology of
  407 SARS-CoV-2 variants in South Korea between January 2020 and February 2023. *Virology*408 2023;**587**:109869.
- 409 25. Nextstrain.org. Genomic epidemiology of SARS-CoV-2 with subsampling focused on
   410 Asia; 2024. Available from: <<u>https://nextstrain.org/ncov/gisaid/asia/6m?dmax=2022-12-15</u>>.
- 411 26. Gwak E, Kim T, Shin JY, Choi NK, Han S, Lee JY, et al. Effectiveness and Safety of
- 412 COVID-19 Vaccination During Preconceptional and Preclinical Pregnancy Period: A National
   413 Population Study. *J Korean Med Sci* 2023;**38**(41):e314.
- 414 27. Park MJ, Choi JH, Cho JH. Estimation of the Effectiveness of a Tighter, Reinforced
- 415 Quarantine for the Coronavirus Disease 2019 (COVID-19) Outbreak: Analysis of the Third
  416 Wave in South Korea. *J Pers Med* 2023;13(3).
- 417 28. Agostini E, Bloise F, Tancioni M. Vaccination policy and mortality from COVID-19 in
- the European Union. *Econom J* 2024;**27**(2):299–322.
- 419 29. Hitchings MDT, Lewnard JA, Dean NE, Ko AI, Ranzani OT, Andrews JR, et al. Use of
- 420 Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of
- 421 COVID-19 Vaccine Effectiveness. *Epidemiology* 2022;**33**(4):450–6.
- 422 30. Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d'Andrea V, et al.
- Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2023;6(5):e2310650.
- 425 31. Liu X, Munro APS, Wright A, Feng S, Janani L, Aley PK, et al. Persistence of immune
- responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK:
- 427 eight-month analyses of the COV-BOOST trial. J Infect 2023;87(1):18–26.
- 428 32. Park SK, Choe YJ, Choe SA, Cowling BJ, Hwang JH, Lee JH, et al. Comparative
- 429 Effectiveness of BNT162b2 and NVX-CoV2373 Vaccines in Korean Adults. *medRxiv* [preprint]
- 430 2023. DOI: <u>10.1101/2023.02.18.23286136</u>.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 431 33. Kim HK, Park SK, Choe SA, Gwak ES, Cowling BJ, Kim YM, et al. Risk of SARS-
- 432 CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean
- 433 Adults: A population-based observational study. *Vaccine* 2024;**42**(7):1440–4.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 435 Table 1

436 Matched participant baseline characteristics for third and fourth doses, by vaccine type.

	Third dose			Fourth dose			
Variable, n (%)	NVX-CoV2373 (n=81,724)	BNT162b2 (n=119,506)	aSD <sup>a</sup>	NVX-CoV2373 (n=489,904)	BNT162b2 (489,904)	aSD <sup>a</sup>	
Age							
12–17	20 (0.0)	431 (0.4)	0.05	0 (0.0)	0 (0.0)	_	
18–24	9545 (11.7)	15,834 (13.3)	0.04	407 (0.1)	521 (0.1)	0.01	
25–39	13,648 (16.7)	24,257 (20.3)	0.09	842 (0.2)	1176 (0.2)	0.01	
40–49	22,359 (27.4)	21,106 (17.7)	0.24	3330 (0.7)	2338 (0.5)	0.02	
50–59	18,044 (22.1)	22,767 (19.1)	0.08	84,240 (17.2)	73,537 (15.0)	0.07	
60–69	11,966 (14.6)	19,051 (15.9)	0.04	213,277 (43.5)	220,406 (45.0)	0.03	
70–79	3974 (4.9)	9394 (7.9)	0.13	132,076 (27.0)	134,753 (27.5)	0.01	
≥80	2168 (2.7)	6666 (5.6)	0.15	55,732 (11.4)	57,173 (11.7)	0.01	
Sex							
Male	38,760 (47.4)	49,730 (41.6)	0.12	242,918 (49.6)	243,113 (49.6)	< 0.01	
Female	42,964 (52.6)	69,776 (58.4)	_	246,986 (50.4)	246,791 (50.4)	_	
Non-capital area <sup>b</sup>	39,655 (48.5)	52,288 (43.8)	0.10	285,394 (58.3)	272,387 (55.6)	0.05	
CCI≥3	5045 (6.2)	7371 (6.2)	< 0.01	59,351 (12.1)	60,001 (12.3)	< 0.01	
Disabled	4208 (5.2)	7744 (6.5)	0.06	58,714 (12.0)	59,892 (12.2)	0.01	
Employed	38,719 (47.4)	47,723 (39.9)	0.15	138,183 (28.2)	132,153 (27.0)	0.03	
Income level <sup>c</sup>							
Medical aid beneficiary	2598 (3.2)	5108 (4.4)	0.06	26,921 (5.6)	28,023 (5.8)	0.01	
1Q	10,504 (13.1)	14,722 (12.7)	0.02	73,819 (15.3)	74,188 (15.4)	< 0.01	
2Q	12,945 (16.1)	23,049 (19.8)	0.09	93,727 (19.4)	95,092 (19.7)	0.01	
3Q	18,441 (23.0)	28,875 (24.8)	0.04	102,438 (21.2)	103,770 (21.5)	0.01	
4Q	35,772 (44.6)	44,596 (38.3)	0.13	186,389 (38.6)	182,191 (37.7)	0.02	
Obese (BMI >30kg/m <sup>2</sup> )	2382 (2.9)	2546 (2.1)	0.05	11,797 (2.4)	11,147 (2.3)	0.01	
Current smoker	5695 (7.0)	7232 (6.1)	0.04	27,631 (5.6)	27,598 (5.6)	< 0.01	
Prior SARS-CoV-2 infection	12,078 (14.8)	15,707 (13.1)	0.05	114,233 (23.3)	113,250 (23.1)	< 0.01	

437 <sup>a</sup>aSD values >0.1 indicate a significant imbalance between vaccine groups. <sup>b</sup>Indication of whether participants were living inside

438 or outside of the Seoul capital area. <sup>c</sup>Income was categorized as medical aid beneficiary (no/lowest income) and then into

439 quartiles of 10%–40%, >40%–60%, >60%–80%, and >80%–100%.

440 aSD, absolute standardized difference; BMI, body mass index; CCI, Charleson comorbidity index; Q, quartile.

441

# 443 **Table 2**

444 Incidence rates (IRs) and adjusted hazard ratios (aHRs) for any and severe SARS-CoV-2 infection following third and fourth

445 COVID-19 vaccine doses (presented by risk window since vaccination<sup>a</sup>).

			NVX-CoV	2373		BNT162b2		
Risk window	Dose SARS-CoV-2 infection	Events, n	Time (1000 person-days)	IR (95% CI) <sup>b</sup>	Events, n	Time (1000 person-days)	IR (95% CI) <sup>b</sup>	aHR (95% CI)
30 days	Third							_ 、
	Any	6455	2337	2.76 (2.70-2.83)	9799	3429	2.86 (2.80-2.91)	0.94 (0.91–0.97)
	Severe	10	2451	0.00 (0.00-0.01)	32	3585	0.01 (0.01–0.01)	0.66 (0.32–1.3)
	Fourth							availe
	Any	11,306	14,504	0.78 (0.77-0.79)	9115	14,551	0.63 (0.61–0.64)	1.19 (1.16–1.2)
	Severe	30	14,696	0.00 (0.00-0.00)	21	14,697	0.00 (0.00-0.00)	1.37 (0.78–2.4)
60 days	Third							a ()
	Any	9042	4545	1.99 (1.95–2.03)	15,795	6615	2.39 (2.35–2.43)	0.81 (0.79–0.8)
	Severe	16	4903	0.00 (0.00-0.00)	68	7167	0.01 (0.01–0.01)	0.51 (0.29–0.8)
	Fourth							U 4.
	Any	24,542	28,681	0.86 (0.85-0.87)	23,621	28,789	0.82 (0.81–0.83)	1.00 (0.98–1.02)
	Severe	64	29,391	0.00 (0.00-0.00)	49	29,392	0.00 (0.00-0.00)	1.34 (0.92–1.95)
90 days	Third							onal
	Any	11,318	6684	1.69 (1.66–1.72)	20,046	9656	2.08 (2.05–2.11)	0.79 (0.77–0.8)
	Severe	28	7353	0.00 (0.00-0.00)	88	10,749	0.01 (0.01–0.01)	0.69 (0.45–1.07)
	Fourth							
	Any	57,000	42,209	1.35 (1.34–1.36)	62,023	42,274	1.47 (1.46–1.48)	0.88 (0.87–0.89)
	Severe	135	44,081	0.00 (0.00-0.00)	111	44,083	0.00 (0.00-0.00)	1.27 (0.99–1.64)
120 days	Third							
	Any	14,495	8747	1.66 (1.63–1.68)	25,253	12,560	2.01 (1.99–2.04)	0.80 (0.78–0.81)

Severe	37	9803	0.00 (0.00-0.00)	115	14,329	0.01 (0.01–0.01)	0.69 (0.48–1.01)
Fourth							
Any	91,114	54,631	1.67 (1.66–1.68)	99,656	54,486	1.83 (1.82–1.84)	0.86 (0.86–0.87)
Severe	243	58,764	0.00 (0.00-0.00)	202	58,768	0.00 (0.00-0.00)	1.28 (1.06–1.55)
150 days Third							
Any	19,677	10,683	1.84 (1.82–1.87)	33,689	15,262	2.21 (2.18–2.23)	0.78 (0.77–0.80)
Severe	47	12,253	0.00 (0.00-0.00)	140	17,908	0.01 (0.01–0.01)	0.70 (0.50–0.97)
Fourth							mad
Any	102,982	66,366	1.55 (1.54–1.56)	112,483	65,954	1.71 (1.70–1.72)	0.86 (0.86–0.8)
Severe	294	73,448	0.00 (0.00-0.00)	261	73,453	0.00 (0.00-0.00)	1.19 (1.01–1.4)
180 days Third							und
Any	23,820	12,467	1.91 (1.89–1.94)	40,214	17,722	2.27 (2.25–2.29)	0.78 (0.76-0.72)
Severe	53	14,702	0.00 (0.00-0.00)	148	21,488	0.01 (0.01–0.01)	0.73 (0.53–1.00)
Fourth							Y-NC
Any	106,377	77,899	1.37 (1.36–1.37)	116,057	77,199	1.50 (1.49–1.51)	0.86 (0.86–0.87)
Severe	330	88,131	0.00 (0.00-0.00)	289	88,138	0.01 (0.01–0.01)	1.21 (1.03–1.42)
<sup>a</sup> Risk windows began 7 days post do	se and ran from days 7–37,	7–67, 7–97, 7–12	7, 7–157, and 7–187. <sup>b</sup> Calcul	ated per 1000 pers	on-days.		terna
							tiona
							nse .

447

medRxiv preprint doi: https://doi.org/10.1101/2024.11.26.24317925; this version posted November 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 448 Figure legends

449

- 450 Fig. 1. Study design for relative vaccine effectiveness comparing NVX-CoV2373 and
- 451 BNT162b2.

452

- 453 **Fig. 2**. Cumulative risk of all SARS-CoV-2 infections after receipt of third dose (left) or fourth
- dose (right) of NVX-CoV2373 or BNT162b2. Shaded area presents 95% confidence intervals of
- 455 incidences. Risk windows began 7 days post dose and ran from days 7–37, 7–67, 7–97, 7–127,
- 456 7–157, and 7–187.

- 458 Fig. 3. Adjusted hazard ratios (aHRs) of any or severe SARS-CoV-2 infection after a third or
- fourth dose of NVX-CoV-2373 or BNT162b2. Risk estimates after a third (left panel) or fourth
- 460 (right panel) dose of NVX-CoV2373 versus BNT162b2 is displayed as aHR with 95% CI. Risk
- 461 windows began 7 days post dose and ran from days 7–37, 7–67, 7–97, 7–127, 7–157, and 7–187.
- aHR values <1 favor protection from SARS-CoV-2 infection with NVX-CoV2373 and >1 favor
- 463 BNT162b2.



<sup>a</sup>Follow-up started 14 days after the second dose of the primary series or 7 days after the third or fourth dose. Risk windows for outcomes were 30-, 60-, 90-, 120-, 150-, and 180-days after start of follow-up. Propensity score matching based on demographic and clinical characteristics and month of vaccination. Homologous and heterologous matching based on dose.

464

Fig. 1. Study design for relative vaccine effectiveness comparing NVX-CoV2373 and BNT162b2. 465





Fig. 2. Cumulative risk of any SARS-CoV-2 infection after receipt of third (left) and fourth (right) doses of NVX-CoV2373 or
 BNT162b2.

It is made available under a CC-BY-NC-ND 4.0 International license



**Fig. 3.** Adjusted hazard ratios (aHR) of any or severe SARS-CoV-2 infection after a third (left panel) or fourth (right panel) dose of

473 NVX-CoV2373 or BNT162b2, by risk window. Risk windows began 7 days post dose and ran from days 7-37, 7-67, 7-97, 7-127, 7-127, 7-157, and 7-187.

475